Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
There was a significant association between the PPARgamma C161T polymorphism and CAD.
|
17892998 |
2007 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
LHGDN |
Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects.
|
17342071 |
2007 |
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is interesting that monocytes from CAD females expressed significantly higher levels of PPAR-gamma protein compared with male patients (p < 0.05) and showed the lowest basal release of tumor necrosis factor-alpha.
|
19644041 |
2009 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease.
|
22987045 |
2012 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined the expression and signaling of NPRs in EAT in the context of CAD progression and their association with brown fat-related genes, such as uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator alpha (PGC1α).
|
31102956 |
2019 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PPARgamma C161-->T substitution is associated with a reduced risk of coronary artery disease (CAD).
|
20334678 |
2010 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene-gene interaction of PPARgamma and ApoE affects coronary heart disease risk.
|
14659862 |
2003 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPARgamma and LPL have intractable roles in pathways that lead to CAD, but their gene polymorphisms associate differently.
|
20430250 |
2010 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of PPAR-γ C1431T-polymorphism with CAD and dyslipidaemia in 787 individuals.
|
25896411 |
2015 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus.
|
11916624 |
2002 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.
|
22515931 |
2012 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-130 negatively correlated with PPAR-γ in both CAD and DM2-CAD group in Pearson's coefficient analysis.
|
31368668 |
2019 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) is associated with increased risk of coronary artery disease: a meta-analysis.
|
23300871 |
2012 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) is implicated in the pathogenesis of CAD.
|
28533333 |
2017 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood.
|
21548985 |
2011 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression was used to observe association of SNP within PPARG and CYP1A1 with CAD risk and GMDR model was used to screen the best interaction combinations.
|
28415751 |
2017 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with the insulin sensitizer PPARγ agonist rosiglitazone in patients with T2DM and CAD is associated with a worsening in aerobic exercise capacity, which seems to be mainly attributable to weight gain and subcutaneous fat mass expansion.
|
30964707 |
2019 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was a significant association between the PPARgamma C161T polymorphism and CAD.
|
17892998 |
2007 |
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Flaxseed Oil Supplementation Improve Gene Expression Levels of PPAR-γ, LP(a), IL-1 and TNF-α in Type 2 Diabetic Patients with Coronary Heart Disease.
|
28916975 |
2017 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the PPARγ C1431T polymorphism is associated with decreased risk of CAD in Chinese Han population.
|
21643757 |
2012 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These long-term findings in patients with manifest CAD support an important role of PPARgamma in determining vascular risk.
|
19228871 |
2009 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Second, we investigated the potential role of PPARγ activators in the prevention of CAD.
|
30156736 |
2018 |
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease.
|
10690291 |
1999 |
Coronary Artery Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease.
|
29441810 |
2018 |
Coronary Artery Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus ADRB2 and GPR74 genes are associated with adipocyte lipolysis, GPR74 also with BMI; PPARG and SREBP1, which promote adipogenesis and lipid storage, are associated with T2D and possible adiposity; ADIPOQ and ARL15 are associated with circulating levels of adiponectin, ARL15 also with coronary heart disease.
|
21036322 |
2010 |